Barclays’s NEVRO CORP. NVRO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-51,151
| Closed | -$299K | – | 5658 |
|
|
2025
Q1 | $299K | Sell |
51,151
-18,265
| -26% | -$96.2K | ﹤0.01% | 3833 |
|
|
2024
Q4 | $258K | Buy |
69,416
+7,920
| +13% | +$36.6K | ﹤0.01% | 4189 |
|
|
2024
Q3 | $344K | Sell |
61,496
-88,518
| -59% | -$619K | ﹤0.01% | 3998 |
|
|
2024
Q2 | $1.26M | Sell |
150,014
-52,672
| -26% | -$562K | ﹤0.01% | 2459 |
|
|
2024
Q1 | $2.93M | Buy |
202,686
+139,900
| +223% | +$2.31M | ﹤0.01% | 2254 |
|
|
2023
Q4 | $1.35M | Buy |
62,786
+45,154
| +256% | +$806K | ﹤0.01% | 3215 |
|
|
2023
Q3 | $339K | Buy |
17,632
+4,133
| +31% | +$88.1K | ﹤0.01% | 3020 |
|
|
2023
Q2 | $343K | Sell |
13,499
-8,458
| -39% | -$244K | ﹤0.01% | 2976 |
|
|
2023
Q1 | $794K | Buy |
21,957
+11,916
| +119% | +$418K | ﹤0.01% | 2914 |
|
|
2022
Q4 | $398K | Buy |
10,041
+7,177
| +251% | +$298K | ﹤0.01% | 3453 |
|
|
2022
Q3 | $134K | Buy |
2,864
+868
| +43% | +$40.3K | ﹤0.01% | 3404 |
|
|
2022
Q2 | $88K | Sell |
1,996
-4,948
| -71% | -$272K | ﹤0.01% | 3825 |
|
|
2022
Q1 | $503K | Sell |
6,944
-121,864
| -95% | -$8.79M | ﹤0.01% | 2905 |
|
|
2021
Q4 | $10.4M | Buy |
128,808
+87,424
| +211% | +$8.76M | ﹤0.01% | 1248 |
|
|
2021
Q3 | $4.82M | Buy |
41,384
+17,220
| +71% | +$2.25M | ﹤0.01% | 1676 |
|
|
2021
Q2 | $4.01M | Sell |
24,164
-21,166
| -47% | -$3.3M | ﹤0.01% | 1728 |
|
|
2021
Q1 | $6.32M | Buy |
45,330
+19,513
| +76% | +$3.18M | ﹤0.01% | 1341 |
|
|
2020
Q4 | $4.47M | Sell |
25,817
-7,649
| -23% | -$1.24M | ﹤0.01% | 1592 |
|
|
2020
Q3 | $4.66M | Buy |
33,466
+3,040
| +10% | +$406K | ﹤0.01% | 1439 |
|
|
2020
Q2 | $3.64M | Buy |
30,426
+20,232
| +198% | +$2.4M | ﹤0.01% | 1618 |
|
|
2020
Q1 | $1.02M | Sell |
10,194
-19,742
| -66% | -$2.37M | ﹤0.01% | 2925 |
|
|
2019
Q4 | $3.52M | Buy |
29,936
+983
| +3% | +$97.4K | ﹤0.01% | 2394 |
|
|
2019
Q3 | $2.49M | Buy |
28,953
+9,884
| +52% | +$748K | ﹤0.01% | 2597 |
|
|
2019
Q2 | $1.24M | Buy |
19,069
+10,370
| +119% | +$646K | ﹤0.01% | 3467 |
|
|
2019
Q1 | $543K | Buy |
8,699
+5,073
| +140% | +$239K | ﹤0.01% | 4032 |
|
|
2018
Q4 | $141K | Sell |
3,626
-46,004
| -93% | -$2.04M | ﹤0.01% | 4818 |
|
|
2018
Q3 | $2.83M | Buy |
49,630
+47,498
| +2,228% | +$2.97M | ﹤0.01% | 2479 |
|
|
2018
Q2 | $170K | Sell |
2,132
-9,931
| -82% | -$824K | ﹤0.01% | 4855 |
|
|
2018
Q1 | $1.04M | Sell |
12,063
-10,242
| -46% | -$827K | ﹤0.01% | 3159 |
|
|
2017
Q4 | $1.54M | Buy |
22,305
+20,338
| +1,034% | +$1.63M | ﹤0.01% | 2691 |
|
|
2017
Q3 | $178K | Sell |
1,967
-9,356
| -83% | -$801K | ﹤0.01% | 4523 |
|
|
2017
Q2 | $843K | Sell |
11,323
-4,263
| -27% | -$342K | ﹤0.01% | 3034 |
|
|
2017
Q1 | $1.46M | Buy |
15,586
+15,188
| +3,816% | +$1.38M | ﹤0.01% | 2378 |
|
|
2016
Q4 | $29K | Sell |
398
-50,759
| -99% | -$4.35M | ﹤0.01% | 5453 |
|
|
2016
Q3 | $5.34M | Buy |
51,157
+39,687
| +346% | +$3.58M | 0.01% | 1238 |
|
|
2016
Q2 | $846K | Buy |
11,470
+11,447
| +49,770% | +$777K | ﹤0.01% | 2759 |
|
|
2016
Q1 | $1K | Sell |
23
-16,332
| -100% | -$963K | ﹤0.01% | 6019 |
|
|
2015
Q4 | $1.1M | Buy |
16,355
+16,268
| +18,699% | +$871K | ﹤0.01% | 2535 |
|
|
2015
Q3 | $4K | Sell |
87
-36,204
| -100% | -$1.75M | ﹤0.01% | 6143 |
|
|
2015
Q2 | $1.92M | Buy |
36,291
+36,017
| +13,145% | +$1.83M | ﹤0.01% | 2253 |
|
|
2015
Q1 | $13K | Sell |
274
-380
| -58% | -$16.5K | ﹤0.01% | 6087 |
|
|
2014
Q4 | $25K | Buy |
+654
| New | +$20.6K | ﹤0.01% | 6198 |
|
Other funds holding NVRO
Barclays's NVRO Position: Q2 2025 in Review
Barclays sold out of NEVRO CORP. (NVRO) in Q2 2025, closing a stake of 51,151 shares — an estimated $299K sold.
Barclays first reported a position in NVRO in Q4 2014 and held it in 42 quarters. The position peaked at $10.4M in Q4 2021. 1 fund tracked by Wall St. Rank holds NVRO as of Q2 2025.
- Barclays reported no remaining NEVRO CORP. position as of Q2 2025 after selling out during the quarter.
- Barclays sold 51,151 NEVRO CORP. shares in Q2 2025, an estimated $299K.
- Barclays first reported a position in NEVRO CORP. in Q4 2014 and held it in 42 quarters.
- Barclays's NEVRO CORP. position peaked at $10.4M in Q4 2021.
- 1 fund tracked by Wall St. Rank held NEVRO CORP. as of Q2 2025.
Based on Barclays's 13F filing for Q2 2025, filed 13 Aug 2025.